Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Total Assets
Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) holds total assets worth CN¥9.87 Billion CNY (≈ $1.44 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Chengdu Kanghong Pharmaceuticals Group C (002773) net assets for net asset value and shareholders' equity analysis.
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's total assets have evolved over time, based on quarterly financial data.
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Chengdu Kanghong Pharmaceuticals Group Co Ltd's total assets of CN¥9.87 Billion consist of 67.3% current assets and 32.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 60.9% |
| Accounts Receivable | CN¥181.63 Million | 1.9% |
| Inventory | CN¥386.86 Million | 4.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥403.70 Million | 4.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Chengdu Kanghong Pharmaceuticals Group C market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chengdu Kanghong Pharmaceuticals Group Co Ltd's current assets represent 67.3% of total assets in 2024, an increase from 47.6% in 2009.
- Cash Position: Cash and equivalents constituted 60.9% of total assets in 2024, up from 22.6% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 13.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 4.3% of total assets.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Total Assets
Key competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.36 | 8.43 | 4.04 |
| Quick Ratio | 9.79 | 7.88 | 3.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.34 Billion | CN¥5.47 Billion | CN¥2.98 Billion |
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Chengdu Kanghong Pharmaceuticals Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.88 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 9.5% |
| Total Assets | CN¥9.34 Billion |
| Market Capitalization | $3.32 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Chengdu Kanghong Pharmaceuticals Group Co Ltd's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Chengdu Kanghong Pharmaceuticals Group Co Ltd's assets grew by 9.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2024)
The table below shows the annual total assets of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥9.34 Billion ≈ $1.37 Billion |
+9.52% |
| 2023-12-31 | CN¥8.53 Billion ≈ $1.25 Billion |
+10.48% |
| 2022-12-31 | CN¥7.72 Billion ≈ $1.13 Billion |
+10.99% |
| 2021-12-31 | CN¥6.96 Billion ≈ $1.02 Billion |
-0.64% |
| 2020-12-31 | CN¥7.00 Billion ≈ $1.02 Billion |
+20.15% |
| 2019-12-31 | CN¥5.83 Billion ≈ $852.68 Million |
+12.17% |
| 2018-12-31 | CN¥5.19 Billion ≈ $760.17 Million |
+13.27% |
| 2017-12-31 | CN¥4.59 Billion ≈ $671.10 Million |
+22.03% |
| 2016-12-31 | CN¥3.76 Billion ≈ $549.94 Million |
+29.54% |
| 2015-12-31 | CN¥2.90 Billion ≈ $424.54 Million |
+49.48% |
| 2014-12-31 | CN¥1.94 Billion ≈ $284.01 Million |
+14.51% |
| 2013-12-31 | CN¥1.69 Billion ≈ $248.03 Million |
+14.41% |
| 2012-12-31 | CN¥1.48 Billion ≈ $216.80 Million |
+14.32% |
| 2011-12-31 | CN¥1.30 Billion ≈ $189.64 Million |
+30.77% |
| 2010-12-31 | CN¥991.06 Million ≈ $145.02 Million |
+20.35% |
| 2009-12-31 | CN¥823.48 Million ≈ $120.50 Million |
-- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.